Pandemic Darlings The pandemic economy, in original documents
Home Source documents Senate Commerce Committee Statement to Senate, No. 791 (June 9, 2022)

Senate Commerce Committee Statement to Senate, No. 791 (June 9, 2022)

Summary

This is a Senate Commerce Committee statement to the New Jersey Senate on Senate Bill No. 791, with committee amendments, dated June 9, 2022. The committee reports the bill favorably. As amended, the bill requires health, hospital, and medical service corporations, health maintenance organizations, and commercial group health insurers to cover an annual prostate cancer screening without cost sharing for men between 40 and 75 years of age. The statement says current law requires coverage only for men age 50 and over who are asymptomatic and men age 40 and over with a family history or other risk factors. The bill widens the definition of screening to include follow-up testing and extends the requirements to other insurers and state health benefits programs.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Senate Commerce Committee Statement to Senate, No. 791 (June 9, 2022).” Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/2022-06-09-scm-s791-s1-afcdb3c5cc/, SHA-256 4d12d30f3ddf4f400553d13280699ee1a3777c5e552c93836fae354e2086b1a3.

Full text

     SENATE COMMERCE COMMITTEE

                    STATEMENT TO

                  SENATE, No. 791
                  with committee amendments



 STATE OF NEW JERSEY
                      DATED: JUNE 9, 2022

   The Senate Commerce Committee reports favorably and with
committee amendments Senate Bill No. 791.
   As amended, this bill requires health, hospital, and medical
service corporations, health maintenance organizations, and
commercial group health insurers to provide coverage for an annual
prostate cancer screening without cost sharing for men who are
between 40 and 75 years of age. Under current law, these health
insurance carriers are required only to provide coverage for an
annual medically recognized diagnostic examination including, but
not limited to, a digital rectal examination and a prostate-specific
antigen test for men age 50 and over who are asymptomatic and for
men age 40 and over with a family history of prostate cancer or
other prostate cancer risk factors. The bill expands the definition of
“prostate cancer screening” to mean medically viable methods for
the detection and diagnosis of prostate cancer, which includes a
digital rectal exam and the prostate-specific antigen test and
associated laboratory work. “Prostate cancer screening” shall also
include subsequent follow up testing as direct by a physician,
including, but not limited to:
   (1) urinary analysis;
   (2) serum biomarkers;
   (3) medical imaging, including, but not limited to, magnetic
resonance imaging.
   The bill also extends the prostate cancer screening requirements
to commercial individual health insurers, health benefits plans
issued pursuant to the New Jersey Individual Health Coverage and
Small Employer Health Benefits Programs, the State Health
Benefits Program, and the School Employees’ Health Benefits
Program, which are not required to provide this coverage under
current law.

COMMITTEE AMENDMENTS
   The committee amended the bill to prohibit cost sharing only for
men 40 to 75 years of age.

File and source

File
2022-06-09_SCM_S791_S1.pdf
Size
113,649 bytes
SHA-256
4d12d30f3ddf4f400553d13280699ee1a3777c5e552c93836fae354e2086b1a3
Our copy
2022-06-09_SCM_S791_S1.pdf
Original
No public link identified.
Back to top